SCHEMBL3094102

SCHEMBL3094102

CCOC(=O)c1ccc(/C=C/CC(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)C(=O)N(CC)c2ccccc2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LARS1 Q9P2J5 1/20 0.42
PPARG P37231 1/20 0.42
GAA P10253 4/20 0.41
POLB P06746 1/20 0.40
RECQL P46063 1/20 0.40
SLC16A3 O15427 1/20 0.40
ALDH1A1 P00352 3/20 0.39
PLAU P00749 1/20 0.38
PIN1 Q13526 1/20 0.38
HIF1A Q16665 1/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 1/20 0.38
RAPGEF3 O95398 1/20 0.37
BCL2 P10415 1/20 0.37
BCL2L1 Q07817 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.36
CA12 O43570 1/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3094115 1.00 LARS1 (0.42) LARS1PPARGGAAPOLBRECQL
SCHEMBL3085146 0.89 LARS1 (0.46) LARS1GAASLC16A3ALDH1A1KMT2A
SCHEMBL3085143 0.89 LARS1 (0.46) LARS1GAASLC16A3ALDH1A1KMT2A
SCHEMBL3090298 0.88 RAPGEF3 (0.48) LARS1SLC16A3ALDH1A1PLAUKMT2A
SCHEMBL3090303 0.88 RAPGEF3 (0.48) LARS1SLC16A3ALDH1A1PLAUKMT2A
SCHEMBL3096816 0.88 LARS1 (0.44) LARS1GAASLC16A3ALDH1A1PLAU
SCHEMBL3097600 0.88 LARS1 (0.43) LARS1GAASLC16A3PIN1KMT2A
SCHEMBL3097592 0.88 LARS1 (0.43) LARS1GAASLC16A3PIN1KMT2A
SCHEMBL3090337 0.84 POLB (0.44) LARS1GAAPOLBRECQLSLC16A3
SCHEMBL3085246 0.83 LARS1 (0.42) LARS1GAAALDH1A1PIN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 LARS1 1976/4885PPARG 136/4885GAA 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.